Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.43 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183147 | 0.88 | ADORA3 (0.59) | CDK2CCNA2CCNA1CDK5CDK5R1 | |
| SCHEMBL183493 | 0.86 | KCNN3 (0.58) | CDK2ADORA3ADORA2AADORA1PDE5A | |
| SCHEMBL183290 | 0.86 | CCNE2 (0.59) | CDK2ADORA3ADORA2AADORA1PDE5A | |
| SCHEMBL183297 | 0.86 | KCNN3 (0.58) | CDK2ADORA3ADORA2AADORA1PDE5A | |
| SCHEMBL183270 | 0.85 | BCDIN3D (0.46) | CDK2ADORA3ADORA2AADORA1PDE5A | |
| SCHEMBL183372 | 0.83 | CDK1 (0.46) | CDK2ADORA3ADORA2AADORA1PDE5A | |
| SCHEMBL13363593 | 0.83 | PDE5A (0.45) | CDK2ADORA3ADORA2AADORA1PDE5A | |
| SCHEMBL19498626 | 0.83 | KCNN3 (0.45) | CDK2ADORA3ADORA2AADORA1PDE5A | |
| SCHEMBL13708308 | 0.81 | CDK1 (0.49) | CDK2CCNA2CCNA1CDK5CDK5R1 | |
| SCHEMBL183231 | 0.81 | CDK2 (0.70) | CDK2CCNA2CCNA1CDK5DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| EP-2142546-B1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | SANIONA AS (DK) | 2017-06-07 | — | — | EP | disclosed |
| EP-2142546-B1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | SANIONA AS (DK) | 2017-06-07 | — | — | EP | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| CN-101646669-B | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH AS | 2013-09-04 | — | — | CN | disclosed |
| US-20130109704-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2013-05-02 | — | — | US | disclosed |
| US-20130109704-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2013-05-02 | — | — | US | disclosed |
| US-8362024-B2 | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| EP-2402341-A2 | Purinyl derivatives and their use as potassium channel modulators | NeuroSearch A/S (DK) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402341-A2 | Purinyl derivatives and their use as potassium channel modulators | NeuroSearch A/S (DK) | 2012-01-04 | — | — | EP | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| CN-101646669-A | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH AS DK | 2010-02-10 | — | — | CN | disclosed |
| EP-2142546-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008116909-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116909-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109704-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | CDK2 3528/4885CCNA2 4698/4885CCNA1 4793/4885 |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | CDK2 3528/4885CCNA2 4698/4885CCNA1 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.